BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rino Y, Yukawa N, Yamamoto N. Does herbal medicine reduce the risk of hepatocellular carcinoma? World J Gastroenterol 2015; 21(37): 10598-10603 [PMID: 26457019 DOI: 10.3748/wjg.v21.i37.10598] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Su CM, Wang HC, Hsu FT, Lu CH, Lai CK, Chung JG, Kuo YC. Astragaloside IV Induces Apoptosis, G1-Phase Arrest and Inhibits Anti-apoptotic Signaling in Hepatocellular Carcinoma. In Vivo 2020;34:631-8. [PMID: 32111763 DOI: 10.21873/invivo.11817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
2 Tsai TY, Livneh H, Hung TH, Lin IH, Lu MC, Yeh CC. Associations between prescribed Chinese herbal medicine and risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide population-based cohort study. BMJ Open. 2017;7:e014571. [PMID: 28122837 DOI: 10.1136/bmjopen-2016-014571] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
3 Yan F, Feng M, Wang X, Wang P, Xie Y, Liu X, Li W, Yang Z. Molecular targets of Yangyin Fuzheng Jiedu Prescription in the treatment of hepatocellular carcinoma based on network pharmacology analysis. Cancer Cell Int 2020;20:540. [PMID: 33292207 DOI: 10.1186/s12935-020-01596-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ishikawa S, Ishikawa T, Tezuka C, Asano K, Sunagawa M, Hisamitsu T. Efficacy of Juzentaihoto for Tumor Immunotherapy in B16 Melanoma Metastasis Model. Evid Based Complement Alternat Med 2017;2017:6054706. [PMID: 28286532 DOI: 10.1155/2017/6054706] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]